

Kaihan Therapeutics

REJUMÉ

Skin Booster

A soybean's survival molecule, engineered into clinical brightening.

Glyceollin-powered

Four pathways

Clinically documented

Commercial & Clinical Overview | 2026



One active. Four pigmentation pathways. A protocol your clinic can run this week

10×

lower dose than arbutin

10 μ M glyceollin against 100 μ M arbutin, with a stronger result.

80%

intracellular melanin reduction

Measured at just 10 μ M in cell assays.

4

independent pathways

Tyrosinase, cAMP/MITF, SCF/c-kit and angiogenesis, all addressed by one active.

3 yrs

predicted shelf life

Confirmed by an independent accelerated-aging study.

Patients ask for brighter, calmer, more even skin.

REJUMÉ gives your clinic a protocol-ready booster for pigmentation that has plateaued under laser alone, and it layers cleanly onto the devices you already own.

Every whitening active trades something away

Conventional agents each intervene at a single point in melanin synthesis, and each carries a compromise.



Hydroquinone

Blocks tyrosinase activity

High efficacy, but skin irritation, hypopigmentation and carcinogenicity concerns.



Arbutin

Blocks tyrosinase activity

Safer, but costly, and may convert to hydroquinone in skin.



Vitamin C

Blocks tyrosine oxidation

Low irritation, but water-soluble, so skin absorption is poor.



Niacinamide

Blocks melanosome transfer

High safety, but modest efficacy and limited comparative data.



Retinoids

Speeds keratinocyte turnover

Rarely used alone: redness, flaking and irritation risk.

The gap in the market

Safe, potent, low-dose and multi-pathway in one active: glyceollin.

Born under attack: the soybean's own defense molecule

Soybeans synthesize glyceollin only when they are threatened by pathogens or severe stress. That is why it is almost absent from market soybeans, and why it was historically too scarce and costly to use.




First identified by the USDA in 1900, as an isoflavonoid-derived defense compound in legumes.



A defense compound the plant makes on demand, only when it is under attack.



Researched in the US and Japan as an anti-ageing and anti-cancer candidate, and now commercialized for aesthetics in Korea.



Glyceollin I, II and III: a natural complex, not a single isolated compound.

338.4 Da

Molecular weight suited to efficient transdermal absorption.

Reference research on the molecule


MCF-7 cell growth -53.4%

BG-1 cell growth -73.1%

E2-stimulated model, 20 mg/kg/mouse/day

A 10× yield breakthrough turned a rare molecule into a scalable active

Glyceollin content from soybean (%)



1 Input

A specially developed soybean cultivar (Glycine max), in 1,000 kg-class batches.

2 Elicitation

Controlled biological stress activates the plant's defense response.

3 Extraction window


A 7-day process yields a glyceollin complex above 1%.

4 Verification

HPLC chromatogram confirms isoform concentration.

Four independent hits on the melanin signal


Where single-pathway actives stop, glyceollin intervenes at four separate points in pigmentation biology.



Stronger melanin control at one-tenth the dose

Glyceollin at 10 μ M against arbutin at 100 μ M, the category's leading safe whitening agent.

Reduction versus control (%)



10×


lower dose than arbutin for a dramatically stronger result.

up to 8×

stronger melanin synthesis inhibition than arbutin, through the most effective known tyrosinase-inhibition mechanism.

The signaling data behind the result

SCF / c-kit pathway: activity reduction vs control (%)



cAMP / MITF blockade

cAMP falls 55-60% through adenylyl cyclase inhibition. Western blot shows a dose-dependent drop in TRP-1, TRP-2, tyrosinase and MITF protein under α -MSH challenge (0.1 to 10 nM).

Reference study

Inhibitory effect of glyceollin isolated from soybean against melanogenesis in B16 melanoma cells. BMB Reports 2010;43(7):461-7. PMID 20663406.

Glyceollin inhibited tyrosinase and TRP-1 expression and suppressed intracellular cAMP induced by α -MSH, without cytotoxicity.

Beyond whitening: calmer, clearer, more resilient skin

The biology



Antioxidant defense

Activates the Nrf2 / GSH pathway for enhanced cellular defense and reduced ROS damage.



Anti-inflammatory action

Suppresses IL-6, iNOS and COX-2 expression through NF-κB-mediated cytokine modulation.



Estrogen-receptor balance

Balanced ER agonist and antagonist activity with EMT inhibition, supporting overall skin health.

What your patient sees

● Brighter, even tone

Multi-pathway control of melanin, including SCF/c-kit and MITF.

● Fewer relapses after laser

Anti-inflammatory action limits post-laser hyperpigmentation and re-pigmentation.

● Calmer, stronger barrier

Nrf2 antioxidant mechanism supports barrier condition and radiance.

● Smoother texture

Sebum oxidative stress modulation for a refined, smooth finish.

Edible-grade, plant-derived and non-cytotoxic

95-120%

cell viability, 0-50 μ M

B16 melanoma MTT assay shows stable viability across the whole dose range: no dose-dependent toxicity.



Natural origin

A soybean-derived compound, non-toxic and edible-grade, with no synthetic whitening chemistry.



No cytotoxicity

Confirmed in cell studies, with stable viability at every tested dose.



No reported adverse effects

No serious side effects reported across in-vitro, in-vivo (zebrafish, chick embryo) and clinical use to date.

Reference study

BMB Reports 2010;43(7):461-7, PMID 20663406: tyrosinase and TRP-1 inhibited, intracellular cAMP suppressed, without cytotoxicity.

The only active that scores well on every dimension at once

Active	Safety	Efficacy	Absorption	Cost
Hydroquinone	Carcinogenic risk	High	Moderate	Low
Arbutin	Safe	Moderate	Moderate	High
Niacinamide	Safe	Low	Low	Low
Glyceollin (REJUMÉ)	Edible-grade	Highest	Excellent	Reasonable



Safe

Non-toxic, soybean-derived and edible-grade. No cytotoxicity in cell studies.



Effective

The most effective known whitening mechanism, at up to 8× the potency of arbutin.



Efficient

A stronger effect at a fraction of the dose, improving cost-efficiency per treatment.



Multi-action

Tyrosinase, MSH pathway, SCF/c-kit, angiogenesis and antioxidant action in one active.

REJUMÉ Skin Booster: a dual-vial clinical system



Ampoule 3 mL

Glyceollins 2.00% with sodium hyaluronate 0.50%: the brightening and hydration active.

Solution 6 mL

Glutathione, L-arginine, L-carnitine, L-glutamine, glycyrrhizic acid and magnesium. Balances osmotic pressure for comfortable delivery.

One box = 9 mL

Mixed ampoule and solution treat up to 2 patients. Once mixed, keeps 1 week refrigerated.

One set = 5 boxes

Up to 10 patient treatments from a single set.

Melasma

Blemishes

Pigmentation

Dull tone

Reduced elasticity

Acne scarring

Fully disclosed formulation

Every ingredient and percentage, listed by INCI name.

Ampoule 3 mL

Ingredient	%	Function
Water	96.07	Solvent
Glyceollins	2.00	Skin conditioning agent
Sodium Chloride	0.75	Viscosity increasing agent
Sodium Hyaluronate	0.50	Skin conditioning agent
Polysorbate 20	0.50	Surfactant (solubilizing agent)
Disodium Phosphate	0.13	Buffering agent
Sodium Phosphate	0.05	pH adjuster

Active core

Glyceollins at 2.00% deliver the multi-pathway brightening. Sodium hyaluronate and the amino-acid and glutathione solution support hydration, barrier and delivery.

Solution 6 mL

Ingredient	%	Function
Water	91.55	Solvent
Glycerin	1.50	Water-soluble thickener
Butylene Glycol	1.50	pH adjuster
Arginine (L)	1.20	Antioxidant
Sodium Chloride	0.82	Skin conditioning agent
Magnesium Chloride	0.65	Skin conditioning agent
Glucose (D)	0.50	Skin conditioning agent
Glutathione	0.50	Skin conditioning agent
1,2-Hexanediol	0.50	Skin conditioning agent
Carnitine	0.45	Skin conditioning agent
Glutamine (L)	0.35	Skin conditioning agent
Glycyrrhizic Acid	0.30	Skin conditioning agent
Trisodium Phosphate	0.13	Skin conditioning agent
Disodium Phosphate	0.05	Skin conditioning agent

Export-grade quality, proven stable for three years

GMP

GMP

Manufacturing and quality management

ISO

ISO 22716:2007

Cosmetics good manufacturing practice

ISO

ISO 13485:2016

Medical device quality management

pH across 194 days at 45°C



Day 0 Day 60 Day 120 Day 194

Specification 3.0 to 9.0

Bacteria and fungi: <10 CFU/g at every time point (limit ≤1,000)

Appearance unchanged from day 0.

3 years

predicted real-time shelf life. 194 days at 45°C is equivalent to 3 years at 20°C (Q10 = 2.0).

Batch release

Pb < 20 ppm

As < 10 ppm

Hg < 1 ppm

Total aerobic count ≤ 1,000 CFU/mL

pH 3.0 to 9.0

All results: pass

Stability testing by Korea Conformity Laboratories (KCL), an independent test laboratory.

Documented in practice: the 7-Day Reset Program

A structured clinical documentation program tracking tone, texture and pigmentation across real patients.



Case A: tone and dullness, after a single session

~40%

reduction in dullness from melasma and blemishes after a single session

83.4%

patient-reported satisfaction with skin-tone improvement

66.7%

patient-reported satisfaction with skin-texture improvement

Reported improvement by case



Result range across 8 documented cases (2 weeks to 3 months)

Tone and pigmentation 25-45% | Cheek and malar pigmentation 35-40% | Texture and blemish 50% | Redness and barrier 60-80%

Documented results: tone, pigmentation and texture



Case B: tone and pigment

Before, 2 weeks, 4 weeks

25% to 45%

tone improvement



Case C: tone uniformity and blemishes

Before, 2 weeks, 4 weeks

35% to 40%

cheek pigmentation and tone gain



Case D: brown pigment and melasma

Before, 2 weeks (marked area)

35%

pigment contrast eased



Case E: texture, blemishes and dullness

Before, 3 weeks

50%

smoother, more even tone

Documented results: redness, sensitivity and inflamed skin




Case F: facial redness

Before and after 9 weeks

60%

barrier, redness and tone
uniformity



Case G: reactive skin

Before and after follow-up

60%

redness, dryness and small
inflammatory marks



Case H: atopic-prone skin

Before and after follow-up

80%

redness, dryness and
inflammatory marks

Six clinician-documented cases: melasma and post-inflammatory pigmentation



Case 1

Pigment around the right eye faded and narrowed. Overall skin tone brighter.



Case 2

Dark areas around the eyes, cheek melasma and overall tone lifted.



Case 3

Injection dermatitis and folliculitis calmed with no residual pigment. Dark lesions approached normal tone.



Case 4

Post-laser pigmentation at eye and cheek lightened close to normal skin colour.



Case 5

Pigment lesions and melasma around the eyes faded evenly.



Case 6

Post-laser pigmentation beneath the eye faded.

Procedure-level results: the 5-session protocol

Documented outcomes presented at ASLS Tokyo 2026.



Meso-roller + laser

5 sessions: persistent melasma, with visible brightening and a more even tone.



MTS protocol

5 sessions: inflammatory lesions and post-inflammatory marks, with visibly calmer skin.

Six patient profiles that fill your treatment room



Dull, dark and dry skin

Patients with overall lackluster tone and compromised hydration.



Stubborn pigmentation

Pigmented lesions that have plateaued under laser-only treatment.



Redness and flushing

Persistent facial redness or reactive flushing patterns.



Chronic acne

Active acne with recurring inflammatory episodes.



Weakened skin barrier

Frequent sensitivity, reactivity or barrier-related skin problems.




General radiance goals

Patients seeking a visible, healthy glow as a primary goal.

Core protocol: Auto-MTS with LDM

The standard brightening and regeneration protocol, and the ideal foundation before any laser or minor procedure.



Core mechanism

Glyceollin performs an antioxidant role in place of melanin, fundamentally suppressing pigment generation.



Post-care: diligent sunscreen application right after the procedure preserves and maximizes the whitening effect.

Fits the equipment and activates your clinic already uses

Compatible delivery methods



Auto-MTS



CO2 laser



Ultrasound



Meso-roller



Needle-RF



**Multi-needle
injector**

Recommended combination protocols



REJUMÉ + pico-toning + 1064 long-pulsed laser

Layered pigment clearance with a brightening base.



Reju-Exos: REJUMÉ + exosomes

Regeneration-focused combination.



Reju-Velook: REJUMÉ + PDLLA

Brightening with a collagen-stimulating volumizer.



Reju-PN: REJUMÉ + polynucleotide (PN)

Brightening with polynucleotide regeneration.

Treatment schedule and protocols by indication

Initial

5 sessions

at 2-4 week intervals

Maintenance

1-2 sessions

every 3 months

Korea clinic reference: KRW 500,000-600,000 per treatment

Indication	Recommended combination
Melasma treatment	Q-switch, picosecond or long-pulse laser + REJUMÉ with MTS, then LDM
Melasma and brightening	Nd:YAG toning laser + REJUMÉ (2 cc), then LDM or iontophoresis
Melasma and pigmentation	Fractional laser or plasma RF + REJUMÉ + LDM
Acne treatment	Extraction, acne laser, Jessner's peel, REJUMÉ MTS, then LDM
Brightening and texture	REJUMÉ 3.0 cc + HA 1.0 cc + BoNT 20 u mix via 0.8 mm injector
Brightening and regeneration	REJUMÉ + exosome or PDRN (1:1), Auto-MTS, then LDM or iontophoresis
General skin booster	REJUMÉ with Auto-MTS, then LDM (device-assisted)
Injector protocol	REJUMÉ 2 cc + non-crosslinked HA 1 cc + BoNT 0.5 cc + PDRN 1 cc via injector

“A game changer for skin brightening”

Conclusion of the glyceollin clinical presentation at ASLS Tokyo 2026, by a Seoul aesthetic physician.

- ✓ Organic, plant-origin active
- ✓ Easy and safe to use in the clinic
- ✓ Fast brightening and moisturizing effect
- ✓ Dual cosmetic and therapeutic action
- ✓ Easy to combine with other treatment modalities
- ✓ A genuinely new, compelling item for the medical aesthetic market

What it means for your clinic



A new, differentiated item

A glyceollin mechanism in a category crowded with the same few actives.



Runs on equipment you own

Layers onto MTS, lasers, RF and injectors, so no new capital outlay.



Built-in repeat visits

Five initial sessions, then maintenance every 3 months.



Simple logistics

One set supports up to 10 patient treatments.

Already active across nine markets, and growing

East Asia

- South Korea
- China
- Mongolia

Southeast Asia

- Vietnam
- Thailand
- Indonesia

Middle East

- U.A.E.
- Saudi Arabia

Eurasia

- Russia

9

export and partner markets

Made in Korea to export-grade standards

- ✓ GMP
- ✓ ISO 13485:2016
- ✓ ISO 22716:2007
- ✓ Korean Venture Business certification

Partner with REJUMÉ

Bring a documented, multi-pathway brightening active to your clinic.



Evaluation samples



Clinical and quality dossier



Protocol guidance



Supply and price list

Kaihan Therapeutics

Hans Jung, CEO

hans@kaihantherapeutics.com | kaihantherapeutics.com

8, Eyewear 3-ro, A-dong, Hayang-eup, Gyeongsan-si, Gyeongsangbuk-do, Republic of Korea

